ENLIVEX THERAPEUTICS LTD's ticker is ENLV and the CUSIP is M4130Y106. A total of 26 filers reported holding ENLIVEX THERAPEUTICS LTD in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,766 | -39.4% | 44,156 | +0.7% | 0.00% | – |
| Q2 2023 | $115,209 | -21.2% | 43,851 | +9.2% | 0.00% | – |
| Q1 2023 | $146,179 | -8.8% | 40,159 | -1.4% | 0.00% | – |
| Q4 2022 | $160,358 | -15.2% | 40,726 | -8.5% | 0.00% | – |
| Q3 2022 | $189,000 | +27.7% | 44,516 | +36.0% | 0.00% | – |
| Q2 2022 | $148,000 | +22.3% | 32,725 | +51.7% | 0.00% | – |
| Q1 2022 | $121,000 | +13.1% | 21,575 | +25.7% | 0.00% | – |
| Q4 2021 | $107,000 | -41.5% | 17,161 | -7.5% | 0.00% | – |
| Q3 2021 | $183,000 | +45.2% | 18,543 | +31.5% | 0.00% | – |
| Q2 2021 | $126,000 | -26.7% | 14,102 | -9.2% | 0.00% | – |
| Q1 2021 | $172,000 | +616.7% | 15,531 | +453.5% | 0.00% | – |
| Q4 2020 | $24,000 | – | 2,806 | +140200.0% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 2 | -100.0% | 0.00% | – |
| Q1 2020 | $132,000 | – | 28,149 | +1407350.0% | 0.00% | – |
| Q4 2019 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACT CAPITAL MANAGEMENT, LLC | 15,000 | $68,000 | 0.10% |
| Susquehanna International Group Ltd. | 22,002 | $98,000 | 0.02% |
| ARK Investment Management | 331,001 | $1,658,000 | 0.01% |
| Compagnie Lombard Odier SCmA | 50,000 | $223,000 | 0.01% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 13,000 | $59,000 | 0.00% |
| OSAIC HOLDINGS, INC. | 400 | $2,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,215 | $5,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 12,373 | $56,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 2,884 | $13,000 | 0.00% |